These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19278300)

  • 1. Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
    Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M;
    Expert Opin Biol Ther; 2009 Apr; 9(4):387-97. PubMed ID: 19278300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
    Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
    Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
    Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
    Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
    Malucchi S; Sala A; Gilli F; Bottero R; Di Sapio A; Capobianco M; Bertolotto A
    Neurology; 2004 Jun; 62(11):2031-7. PubMed ID: 15184610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau AJ; White RA; Ebers GC; Reder AT; Sibley WA; Lublin FD; Paty DW;
    Mult Scler; 2004 Apr; 10(2):126-38. PubMed ID: 15124756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Rivoiro C; Ferrero C; Picco E; Ripellino P; Giuliani G; Montanari E; Clerico M;
    J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):646-51. PubMed ID: 17986500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
    Gottesman MH; Friedman-Urevich S
    Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical approaches to assessing the effects of neutralizing antibodies: IFNbeta-1b in the pivotal trial of relapsing-remitting multiple sclerosis.
    Petkau AJ; White R
    Neurology; 2003 Nov; 61(9 Suppl 5):S35-7. PubMed ID: 14610111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
    Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
    Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy.
    Lanzillo R; Orefice G; Prinster A; Ventrella G; Liuzzi R; Scarano V; Florio C; Vacca G; Brunetti A; Alfano B; Brescia Morra V; Bonavita V
    Neurol Sci; 2011 Apr; 32(2):287-92. PubMed ID: 21308385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.